N. S. Sirisoma et al. / Bioorg. Med. Chem. Lett. 11 (2001) 2979–2981
2981
2. Barnard, E. A.; Skolnick, P.; Olsen, R. W.; Mohler, H.;
Sieghart, W.; Biggio, G.; Braestrup, C.; Bateson, A. N.; Lan-
ger, S. Z. Pharmacol. Rev. 1998, 50, 291.
3. Smith, G. B.; Olsen, R. W. Trends Pharmacol. Sci. 1995, 16,
162.
4. Smith, G. B.; Olsen, R. W. Neuropharmacology 2000, 39, 55.
5. Casida, J. E.; Pulman, D. A. In Advances in the Chemistry
of Insect Control III; Briggs, G. G., Ed.; Proc 3rd Intl. Symp.
Adv. Chem. of Insect Control, Spec. Publ. 147, 1994; p 36.
6. Bloomquist, J. R. In Biochemical Sites of Insecticide Action
and Resistance; Ishaaya, I., Ed.; Springer: Berlin, 2001; p 17.
7. Colliot, F.; Kukorowski, K. A.; Hawkins, D. W.; Roberts,
D. A. In Brighton Crop Protection Conference—Pests and
Diseases; British Crop Protection Council: Farnham, UK,
1992; Vol. 1, p 29.
8. Cole, L. M.; Nicholson, R. A.; Casida, J. E. Pestic. Bio-
chem. Physiol. 1993, 46, 47.
9. Hainzl, D.; Casida, J. E. Proc. Natl. Acad. Sci. U.S.A.
1996, 93, 12764.
10. Hainzl, D.; Cole, L. M.; Casida, J. E. Chem. Res. Toxicol.
1998, 11, 1529.
11. Ozoe, Y.; Yagi, K.; Nakamura, M.; Akamatsu, M.; Miyake,
T.; Matsumura, F. Pestic. Biochem. Physiol. 2000, 66, 92.
12. Brunner, J.; Senn, H.; Richards, F. M. J. Biol. Chem.
1980, 255, 3313.
ꢃ0.5 mL NH3 was condensed into it. The screw cap was
closed tightlyand the mixture was stirred overnight at room
temperature. The residue after removing the white precipitate
was chromatographed with 15% ethyl acetate in hexane to
obtain 7 (oil, 202 mg, 0.516 mmol, 72%) which is stable for
several months at ꢀ20 ꢂC.
19. To 7 (202 mg, 0.516 mmol) in dryether (4 mL) was added
14
freshlyprepared
Ag2O (500 mg, 2.16 mmol). After 45 min,
the mixture was filtered, concentrated, and chromatographed
(3% ethyl acetate in hexane) to obtain 3 (oil, 194 mg, 0.50
mmol, 97%). Compound 3 is much less stable than immediate
precursor 7, so the final conversion step should be carried out
shortlybefore use.
20. 1H NMR (CDCl3, 300 MHz, d) for pyrazole H3 and H5,
respectively: 3 7.68 and 7.55; 4 7.80 and 7.61; 5 8.38 and 8.30;
6 8.44 and 8.26; 7 7.96 and 7.82. 13C NMR (CDCl3, 75 MHz,
d) for CF3 and pyrazole C3, C4 and C5, respectively: 3, 121.8,
139.8, 113.5, and 126.0; 4, no CF3, 142.4, 95.4, and 125.9; 5
116.3, 143.0, 117.9, and 126.2; 6 119.9, 146.3, 108.2 and 126.0;
7 123.3, 140.4, 115.8, and 126.6.
21. 3: HRMS (EI) m/z C12H5Cl2F6N4, [MH]+ calcd 388.9796,
found 388.9798; UV (ethanol) mmax 358 nm.
22. Schofield, P. R.; Darlison, M. G.; Fujita, N.; Burt, D. R.;
Stephenson, F. A.; Rodriguez, H.; Rhee, L. M.; Ramachan-
dran, J.; Reale, V.; Glencorse, T. A.; Seeburg, P. H.; Barnard,
E. A. Nature 1987, 328, 221.
13. Nassal, M. Liebigs Ann. Chem. 1983, 1510.
14. Shih, L. B.; Bayley, H. Anal. Biochem. 1985, 144, 132.
15. Bromopyrazole 4 was prepared bybromination of the
corresponding unsubstituted pyrazole with bromine in glacial
acetic acid.
23. Ratra, G. S.; Kamita, S. G.; Casida, J. E. Toxicol. Appl.
Pharmacol. 2001, 172, 233.
24. Ratra, G. S.; Casida, J. E. Toxicol. Lett. 2001, 122, 215.
25. ffrench-Constant, R. H.; Rocheleau, T. A.; Steichen, J. C.;
Chalmers, A. E. Nature 1993, 363, 449.
26. ffrench-Constant, R. H.; Anthony, N.; Aronstein, K.;
Rocheleau, T.; Stilwell, G. Annu. Rev. Entomol. 2000, 48, 449.
27. Littleton, J. T.; Ganetzsky, B. Neuron. 2000, 26, 35.
28. Cole, L. M.; Roush, R. T.; Casida, J. E. Life Sci. 1995, 56,
757.
29. Davies, P. A.; Kirkness, E. F.; Hales, T. G. Br. J. Phar-
macol. 1997, 120, 899.
30. Hedblom, E.; Kirkness, E. F. J. Biol. Chem. 1997, 272,
15346.
31. Cole, L. M.; Casida, J. E. Pestic. Biochem. Physiol. 1992,
44, 1.
16. Bromopyrazole 4 (1.264 g, 3.51 mmol) in dryTHF (12
mL) at ꢀ78 ꢂC was added slowlyto n-butyllithium (1.6 M, 2.6
mL, 4.16 mmol) in dryTHF (20 mL) at ꢀ78 ꢂC. After stirring
for 15 min, EtOC(O)CF3 (1.0 g, 7.0 mmol) was added in THF
(5 mL). The solution was allowed to warm to 20 ꢂC and stirred
for 1 h and 1 mL of saturated NaCl was added. The reaction
mixture was diluted with ethyl acetate (20 mL) and washed
with half-saturated NaCl (50 mL) and saturated NaCl (50 mL)
then the organic layer was dried over MgSO4, filtered, and
concentrated. The residue was chromatographed on silica gel
with 5% ethyl acetate in hexane to obtain 5 (529 mg, 1.40
mmol, 40%).
17. Trifluoromethylketone derivative 5 (529 mg, 1.40 mmol)
was dissolved in pyridine (4.4 mL, dried over CaH2) and eth-
anol (1.8 mL). NH2OH HCl (100 mg, 1.44 mmol) was added
32. The receptor preparations were Drosophila head mem-
branes (300 mg protein/assay) and Sf9 cell membranes expres-
sing recombinant human b3 receptor (250 mg protein/assay).
Assaymixtures contained membrane fraction, various con-
centrations of 1 or 3 dissolved in dimethyl sulfoxide (final
concentration 1%), and 0.8 nM (Drosophila) or 1.0 nM (b3)
[3H]EBOB (30 Ci/mmol) in a total volume of 0.5 mL of 300
mM (for Drosophila) or 200 mM (for b3) sodium chloride/10
mM sodium phosphate buffer (pH 7.5). After 70 min incuba-
tion at 25 ꢂC, the binding reaction was terminated byfiltration
on a GF/B filter (presoaked in 0.1% polyethyleneimine) and
the filter was rinsed three times with ice cold water containing
0.9% sodium chloride/2% ethanol. Specific binding was
defined as the difference in radioactivityon the filter in the
absence and presence of 5 mM a-endosulfan.
.
and the mixture was stirred overnight at 60 ꢂC. The residue
from evaporation was dissolved in ethyl acetate with work up
involving washing with water, 0.1 N HCl and saturated NaCl,
then drying, filtration and concentration. The crude oxime
intermediate (401 mg, 1.02 mmol) was dissolved in anhydrous
pyridine (3.5 mL) at room temperature, tosyl chloride (278
mg, 1.46 mmol) was added and the mixture was refluxed for 4
h. The solvent was evaporated and the residue chromato-
graphed with 4–6% ethyl acetate in hexane to give 6 (490 mg,
0.90 mmol, overall 64%) as a white solid.
18. A solution of 6 (390 mg, 0.714 mmol) in dryether (1.5
mL) in a thick-walled glass tube was cooled to ꢀ78 ꢂC and